MINUTES
About Minutes
Back to latest

HealthJ&J eyes US filing for Caplyta in bipolar mania after second trial win

Johnson & Johnson said its drug Caplyta outperformed placebo in easing manic symptoms in a second late-stage study of people with bipolar I disorder, setting the stage for a planned US regulatory filing.

Johnson & JohnsonCaplytabipolar disorderclinical trials

RReuters★★☆☆☆2026-11-10 14:50Original

J&J eyes US filing for Caplyta in bipolar mania after second trial win
J&J eyes US filing for Caplyta in bipolar mania after second trial winHealth